The pharma sector is in upheaval, with massive deals making weekly headlines and companies taking evasive action to pre-empt the advances of predators. But will separating drugs businesses from consumer healthcare divisions really reap dividends for shareholders? Owain Bennallack takes a look at GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) and Reckitt Benckiser (LSE: RB)…
GlaxoSmithKline plc And Reckitt Benckiser plc Aim To Unlock Value
VIDEO: One Fool puts GlaxoSmithKline plc (LON:GSK) and Reckitt Benckiser plc (LON:RB) under the spotlight.
The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.
You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.